Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Item 9 Labs's 10-Year RORE % for the quarter that ended in Jun. 2023 was 0.00%.
The industry rank for Item 9 Labs's 10-Year RORE % or its related term are showing as below:
INLB's 10-Year RORE % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 6.43 * Ranked among companies with meaningful 10-Year RORE % only.
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Item 9 Labs 10-Year RORE % Related Terms
Item 9 Labs 10-Year RORE % Historical Data
* Premium members only.
The historical data trend for Item 9 Labs's 10-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
INLB vs NEPT, CENBF, SGBI: 10-Year RORE % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Item 9 Labs's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Item 9 Labs 10-Year RORE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Item 9 Labs's 10-Year RORE % distribution charts can be found below:
* The bar in red indicates where Item 9 Labs's 10-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Jun. 2023 and 10-year before.
Item 9 Labs (INLB) has a 10-Year RORE % of 0.00 as of Jun. 2023. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on Item 9 Labs and its competitors.
Is Item 9 Labs' 10-Year RORE % too high?
Item 9 Labs' current 10-Year RORE % is 0.00. Overall, Item 9 Labs has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Item 9 Labs' 10-Year RORE % compare to NEPT and CENBF?
Item 9 Labs' 10-Year RORE % of 0.00 can be compared against companies in the Drug Manufacturers industry. The industry median 10-Year RORE % is 6.43. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year RORE % for a Drug Manufacturers company?
The median 10-Year RORE % among Drug Manufacturers companies is 6.43, based on 671 companies in the industry. Companies in the top quartile (top 25%) have a 10-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 10-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year RORE % mean?
A high 10-Year RORE % can signal that a stock is expensive relative to its fundamentals. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on Item 9 Labs and its competitors. For the Drug Manufacturers industry, the median 10-Year RORE % is 6.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Item 9 Labs's current 10-Year RORE % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Item 9 Labs stock overvalued right now?
Item 9 Labs (INLB) has a current 10-Year RORE % of 0.00. The current 10-Year RORE % is 0.00. Item 9 Labs' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year RORE % calculated?
10-Year RORE % is calculated from a company's financial statements. For Item 9 Labs (INLB), the current 10-Year RORE % is 0.00 as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Item 9 Labs Corp is a vertically integrated cannabis operator and dispensary franchisor delivering premium products from its large-scale cultivation and production facilities in the United States. The Item 9 Labs brand specializes in products and user experience across several cannabis categories. The company also offers a dispensary franchise model through the national Unity Rd. retail brand. Easing barriers to entry, the franchise provides an opportunity for both new and existing dispensary owners to leverage the knowledge, resources, and ongoing support needed to thrive in their state compliantly and successfully. It also brings industry practices to markets nationwide through distinctive retail experience, cultivation capabilities, and product innovation.
12GF Score
Get the complete analysis for INLB
10-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INLB has been successfully added to your 
